Author of

• 16831

  +

  P1.06 - Poster Session with Presenters Present (ID 458)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16876

    +

    P1.06-045 - Multiple Neoplasms Consist of Lung Cancer and Hematological Malignancies (ID 5737)

    14:30 - 14:30  |  Author(s): A. Sakai
    • Abstract

    Background:
    The lung cancer is a cancer of the most in Japan and first place in cause of death. Lung cancer (LC)is still poor prognosis disease that cure only in early clinical stage. We report that we reviewed 55 cases of multiple neoplasms with lung cancer and the hematological malignancies.
    
    Methods:
    We intended for multiple neoplasms 339 cases including hematological malignancy. We reviewed 55 multiple neoplasms including the lung cancer. All patients were followed up until death or untile August 2016. Survival was measured from the diagnosis of multiple cancer to time of death or last contact. Definition of the multiple neoplasms in compliance with Warren & Gates. Also we determined the synchronous type and metachronous type in accordance with the definition of Moertel, so within less than 6 months was synchronous type, more than 6 months was metachronous type.
    
    Results:
    All cases are 55 cases, consist of male 44 cases, female 11 cases, type of multiple neoplasms, synchronous type 14 cases, metachronous type 41 cases. Number of multiple neoplasms, double neoplasms 38 cases, triple neoplasms 14 cases, quadple neoplasms 3 cases. The median age was 71years (range,47-86years) The counterpart of malignancies, MHL 26 cases, MDS 7 cases, AML 7 cases, HL 2 cases, MG 1 case, CLL 2 cases, CML 2 case, ALL 1 case, MGUS 3 cases. In double neoplasms, the median age of first diagnosis, 69years, the second cancer were 71years, About interval between lung cancer and hematological malignancies, lung cancer precedence case was 40M, hematological malignancy precedence case was 54M. The median overall survival was 24M.
    
    Conclusion:
    Diagnosis of LC within 5 years were 26 cases out of 41 cases. The important point is that 5 years are required for careful observation at the time of hematological malignancy diagnosis. We think that a prognosis is improved.
    
    

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17623

    +

    P2.03a-067 - Therapy-Related Leukemia after Lung Cancer Chemotherapy (ID 5734)

    14:30 - 14:30  |  Author(s): A. Sakai
    • Abstract

    Background:
    Therapy-related leukemia defined by the World health Organization 2008 classification scheme of hematolymphoid tumors including therapy-related acute myeloid neoplasms (t-AML), myelodysplastic syndrome (t-MDS). They occur as late complication of cytotoxic chemotherapy, radiation therapy and molecular target agents therapy against primary neoplasms. Recently, for lung cancer chemotherapy, new anti-cancer agent and molecurar target agents are increased and more intensification chemotherapy performed.We report that we reviewed t-AML cases who survived from lung cancer and suffered t-AML.
    
    Methods:
    We intended for multiple neoplasms 339 cases including hematological malignancy. We reviewed 55 multiple neoplasms including the lung cancer. In 55 cases, second neoplasms that were t-AML cases were 4 cases, t-MDS case was 1 case. All patients were followed up until death or untile December 2015. Survival was measured from the diagnosis of multiple cancer to time of death or last contact. We investigated cytogenetic abnormality, therapy, clinical outcome, prognosis, and cause of death.
    
    Results:
    In 5 cases, 4 cases were diagnosed t-AML, 1 case was t-MDS. 5 of cases were 4 male and 1 femal, primaly diagnosis were small cell carcinoma 2 cases, squamous carcinoma adenocarcinoma 3 cases. 1 case, One case(male case) was t-APL, he treated by all-trans retinoic acid and he reached complete response. T-M2 type, hshe treated by chemotherapy included daunorbicin and Ara-C(DC3-7), she did not achieve complete response. About prognosis, t-APL case, he lived 1 month after complete response, he died by lung cancer, t-AML cases, one female case, she lived 25 months after partial response, she died by t-AML relapse and refractory for salvage CTx. Other 3 cases, 1 case death by t-MDS, 2 cases death by t-AML.
    
    Conclusion:
    As the number of lung cancer survivors increased due to improvement in chemotherapy, clinician must more take attention of therapy-related leukemia and myelodysplastic syndrome by previous treatments.